Top

Published in:

01-12-2021 | Frontotemporal Dementia | Research article

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Authors: Longfei Jia, Min Zhu, Jianwei Yang, Yana Pang, Qi Wang, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei

Published in: BMC Medicine | Issue 1/2021

Abstract

Background

The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we report a panel of microRNAs (miRNAs) in serum that can predict P-tau/Aβ42 in CSF and readily differentiate AD from other dementias, including vascular dementia (VaD), Parkinson disease dementia (PDD), behavioral variant frontotemporal dementia (bvFTD), and dementia with Lewy body (DLB).

Methods

RNA samples were extracted from the participant’s blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), is used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test is then applied to a fourth group of patients with different dementias (controls, 139; AD,155; amnestic mild cognitive impairment [aMCI], 55; VaD, 51; PDD, 53; bvFTD, 53; DLB, 52) to assess its diagnostic capacity.

Results

In the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB.

Conclusions

This study suggests that the panel of microRNAs is a promising substitute for traditional measurement of P-tau/Aβ42 in CSF as an effective biomarker of AD.

Available only for authorised users

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–9. https://doi.org/10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–9. https://doi.org/10.1001/archneurol.2008.596.CrossRefPubMed

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15(2):205–16. https://doi.org/10.1016/j.jalz.2018.09.001.CrossRefPubMed

Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 2020;77(8):955–65. https://doi.org/10.1001/jamaneurol.2020.0989.CrossRefPubMed

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. https://doi.org/10.1016/S1474-4422(16)00070-3.CrossRefPubMed

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–34. https://doi.org/10.1016/S1474-4422(06)70355-6.CrossRefPubMed

Lleo A, Irwin DJ, Illan-Gala I, McMillan CT, Wolk DA, Lee EB, et al. A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol. 2018;75(6):738–45. https://doi.org/10.1001/jamaneurol.2018.0118.CrossRefPubMedPubMedCentral

Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. 2018;14(11):1460–9. https://doi.org/10.1016/j.jalz.2018.01.013.CrossRefPubMedPubMedCentral

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis. 2015;44(2):525–39. https://doi.org/10.3233/JAD-141725.CrossRefPubMed

10.

Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, et al. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019;15(8):1071–80. https://doi.org/10.1016/j.jalz.2019.05.002.CrossRefPubMed

11.

Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage. Alzheimers Dement. 2020;17(1):49–60. https://doi.org/10.1002/alz.12166.CrossRefPubMedPubMedCentral

12.

Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252–63. https://doi.org/10.1038/nrm2868.CrossRefPubMed

13.

Zhao Y, Zhang Y, Zhang L, Dong Y, Ji H, Shen L. The potential markers of circulating microRNAs and long non-coding RNAs in Alzheimer’s disease. Aging Dis. 2019;10(6):1293–301. https://doi.org/10.14336/AD.2018.1105.CrossRefPubMedPubMedCentral

14.

Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14(7):R78. https://doi.org/10.1186/gb-2013-14-7-r78.CrossRefPubMedPubMedCentral

15.

van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briede JJ. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol. 2020;185:101732. https://doi.org/10.1016/j.pneurobio.2019.101732.CrossRefPubMed

16.

Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171–86. https://doi.org/10.1007/s00401-017-1717-7.CrossRefPubMedPubMedCentral

17.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRefPubMedPubMedCentral

18.

Humpel C. Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol. 2011;29(1):26–32. https://doi.org/10.1016/j.tibtech.2010.09.007.CrossRefPubMedPubMedCentral

19.

Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006;367(9518):1262–70. https://doi.org/10.1016/S0140-6736(06)68542-5.CrossRefPubMed

20.

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–60. https://doi.org/10.1212/WNL.43.2.250.CrossRefPubMed

21.

Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64(Suppl 2):S81–92. https://doi.org/10.1002/ana.21455.CrossRefPubMed

22.

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77. https://doi.org/10.1093/brain/awr179.CrossRefPubMedPubMedCentral

23.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. https://doi.org/10.1212/WNL.0000000000004058.CrossRefPubMedPubMedCentral

24.

Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain. 2015;138(Pt 9):2716–31. https://doi.org/10.1093/brain/awv181.CrossRefPubMed

25.

Min L, Zhu S, Chen L, Liu X, Wei R, Zhao L, et al. Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancer: a comparison with plasma total miRNAs. J Extracell Vesicles. 2019;8(1):1643670. https://doi.org/10.1080/20013078.2019.1643670.CrossRefPubMedPubMedCentral

26.

Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25. https://doi.org/10.1186/gb-2009-10-3-r25.CrossRefPubMedPubMedCentral

27.

Nawrocki EP, Eddy SR. Infernal 1.1: 100-fold faster RNA homology searches. Bioinformatics. 2013;29(22):2933–5. https://doi.org/10.1093/bioinformatics/btt509.CrossRefPubMedPubMedCentral

28.

Friedlander MR, Chen W, Adamidi C, Maaskola J, Einspanier R, Knespel S, et al. Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol. 2008;26(4):407–15. https://doi.org/10.1038/nbt1394.CrossRefPubMed

29.

Kivioja T, Vaharautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. 2011;9(1):72–4. https://doi.org/10.1038/nmeth.1778.CrossRefPubMed

30.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

31.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

32.

Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914–22. https://doi.org/10.1212/WNL.0b013e3181c47cc2.CrossRefPubMedPubMedCentral

33.

Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558–69. https://doi.org/10.4097/kja.19087.CrossRefPubMedPubMedCentral

34.

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–54. https://doi.org/10.1038/nature25456.CrossRefPubMed

35.

Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease. Alzheimers Dement. 2020;16(4):681–95. https://doi.org/10.1016/j.jalz.2019.09.004.CrossRefPubMedPubMedCentral

36.

Karikari TK, Emersic A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers Dement. 2020.

37.

Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol. 2018;83(3):544–52. https://doi.org/10.1002/ana.25172.CrossRefPubMedPubMedCentral

38.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007–15. https://doi.org/10.1212/WNL.0000000000007032.CrossRefPubMedPubMedCentral

39.

van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103–11. https://doi.org/10.1016/S1474-4422(19)30354-0.CrossRefPubMed

40.

Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157–64. https://doi.org/10.1136/jnnp-2018-318704.CrossRefPubMed

41.

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–33. https://doi.org/10.1016/S1474-4422(20)30071-5.CrossRefPubMed

42.

Hebert SS, Horre K, Nicolai L, Bergmans B, Papadopoulou AS, Delacourte A, et al. MicroRNA regulation of Alzheimer’s Amyloid precursor protein expression. Neurobiol Dis. 2009;33(3):422–8. https://doi.org/10.1016/j.nbd.2008.11.009.CrossRefPubMed

43.

Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem. 2010;285(24):18344–51. https://doi.org/10.1074/jbc.M110.112664.CrossRefPubMedPubMedCentral

44.

Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem. 2012;287(37):31298–310. https://doi.org/10.1074/jbc.M112.366336.CrossRefPubMedPubMedCentral

45.

Liu W, Liu C, Zhu J, Shu P, Yin B, Gong Y, et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol Aging. 2012;33(3):522–34. https://doi.org/10.1016/j.neurobiolaging.2010.04.034.CrossRefPubMed

46.

Manzine PR, Pelucchi S, Horst MA, Vale FAC, Pavarini SCI, Audano M, et al. microRNA 221 targets ADAM10 mRNA and is downregulated in Alzheimer’s disease. J Alzheimers Dis. 2018;61(1):113–23. https://doi.org/10.3233/JAD-170592.CrossRefPubMed

47.

Akhter R, Shao Y, Shaw M, Formica S, Khrestian M, Leverenz JB, et al. Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer’s disease. Neurobiol Aging. 2018;63:110–9. https://doi.org/10.1016/j.neurobiolaging.2017.11.007.CrossRefPubMed

48.

Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17):6415–20. https://doi.org/10.1073/pnas.0710263105.CrossRefPubMedPubMedCentral

49.

Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28(5):1213–23. https://doi.org/10.1523/JNEUROSCI.5065-07.2008.CrossRefPubMedPubMedCentral

50.

Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, et al. microRNA-33 regulates ApoE lipidation and amyloid-beta metabolism in the brain. J Neurosci. 2015;35(44):14717–26. https://doi.org/10.1523/JNEUROSCI.2053-15.2015.CrossRefPubMedPubMedCentral

51.

Zhao Y, Jaber V, Lukiw WJ. Over-expressed pathogenic miRNAs in Alzheimer’s disease (AD) and Prion disease (PrD) drive deficits in TREM2-mediated Abeta42 peptide clearance. Front Aging Neurosci. 2016;8:140. https://doi.org/10.3389/fnagi.2016.00140.CrossRefPubMedPubMedCentral

52.

Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med. 2013;5(10):1613–34. https://doi.org/10.1002/emmm.201201974.CrossRefPubMedPubMedCentral

53.

Zhu QB, Unmehopa U, Bossers K, Hu YT, Verwer R, Balesar R, et al. MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer’s disease. Brain. 2016;139(Pt 3):908–21. https://doi.org/10.1093/brain/awv383.CrossRefPubMed

54.

Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645–59. https://doi.org/10.1523/JNEUROSCI.1327-13.2013.CrossRefPubMedPubMedCentral

55.

Aschrafi A, Schwechter AD, Mameza MG, Natera-Naranjo O, Gioio AE, Kaplan BB. MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J Neurosci. 2008;28(47):12581–90. https://doi.org/10.1523/JNEUROSCI.3338-08.2008.CrossRefPubMedPubMedCentral

56.

Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5. https://doi.org/10.1038/nature07823.CrossRefPubMedPubMedCentral

57.

Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010;6(1):e1000795. https://doi.org/10.1371/journal.pgen.1000795.CrossRefPubMedPubMedCentral

58.

Zhang Y, Liu C, Wang J, Li Q, Ping H, Gao S, et al. MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Sci Rep. 2016;6(1):24566. https://doi.org/10.1038/srep24566.CrossRefPubMedPubMedCentral

59.

Sun J, Gao X, Meng D, Xu Y, Wang X, Gu X, et al. Antagomirs targeting miroRNA-134 attenuates epilepsy in rats through regulation of oxidative stress, mitochondrial functions and autophagy. Front Pharmacol. 2017;8:524. https://doi.org/10.3389/fphar.2017.00524.CrossRefPubMedPubMedCentral

60.

Cheng M, Liu L, Lao Y, Liao W, Liao M, Luo X, et al. MicroRNA-181a suppresses parkin-mediated mitophagy and sensitizes neuroblastoma cells to mitochondrial uncoupler-induced apoptosis. Oncotarget. 2016;7(27):42274–87. https://doi.org/10.18632/oncotarget.9786.CrossRefPubMedPubMedCentral

61.

Kim J, Fiesel FC, Belmonte KC, Hudec R, Wang WX, Kim C, et al. miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Mol Neurodegener. 2016;11(1):55. https://doi.org/10.1186/s13024-016-0121-4.CrossRefPubMedPubMedCentral

62.

Verma P, Augustine GJ, Ammar MR, Tashiro A, Cohen SM. A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity. Nat Neurosci. 2015;18(3):379–85. https://doi.org/10.1038/nn.3935.CrossRefPubMed

63.

Poon VY, Gu M, Ji F, VanDongen AM, Fivaz M. miR-27b shapes the presynaptic transcriptome and influences neurotransmission by silencing the polycomb group protein Bmi1. BMC Genomics. 2016;17(1):777. https://doi.org/10.1186/s12864-016-3139-7.CrossRefPubMedPubMedCentral

64.

Hu Z, Li Z. miRNAs in synapse development and synaptic plasticity. Curr Opin Neurobiol. 2017;45:24–31. https://doi.org/10.1016/j.conb.2017.02.014.CrossRefPubMedPubMedCentral

65.

Takousis P, Sadlon A, Schulz J, Wohlers I, Dobricic V, Middleton L, et al. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid. Alzheimers Dement. 2019;15(11):1468–77. https://doi.org/10.1016/j.jalz.2019.06.4952.CrossRefPubMed

66.

Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract. 2010;206(8):578–84. https://doi.org/10.1016/j.prp.2010.03.005.CrossRefPubMed

67.

Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54(10):1716–24. https://doi.org/10.1373/clinchem.2008.109603.CrossRefPubMedPubMedCentral

68.

Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Munzel T, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur Heart J. 2017;38(7):516–23. https://doi.org/10.1093/eurheartj/ehw250.CrossRefPubMed

69.

Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS One. 2015;10(12):e0145930. https://doi.org/10.1371/journal.pone.0145930.CrossRefPubMedPubMedCentral

70.

Liu Y, Gao G, Yang C, Zhou K, Shen B, Liang H, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci. 2014;15(6):10567–77. https://doi.org/10.3390/ijms150610567.CrossRefPubMedPubMedCentral

71.

Yang Z, Chen H, Si H, Li X, Ding X, Sheng Q, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 2014;51(5):823–31. https://doi.org/10.1007/s00592-014-0617-8.CrossRefPubMed

72.

Riancho J, Vazquez-Higuera JL, Pozueta A, Lage C, Kazimierczak M, Bravo M, et al. MicroRNA profile in patients with Alzheimer’s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. J Alzheimers Dis. 2017;57(2):483–91. https://doi.org/10.3233/JAD-161179.CrossRefPubMed

73.

Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H. MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One. 2015;10(5):e0126423. https://doi.org/10.1371/journal.pone.0126423.CrossRefPubMedPubMedCentral

74.

Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, Wojda U. microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. 2019;49:125–43. https://doi.org/10.1016/j.arr.2018.10.008.CrossRefPubMed

75.

Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, et al. Validating Alzheimer’s disease micro RNAs using next-generation sequencing. Alzheimers Dement. 2016;12(5):565–76. https://doi.org/10.1016/j.jalz.2015.12.012.CrossRefPubMed

Title: Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
Authors: Longfei Jia
Min Zhu
Jianwei Yang
Yana Pang
Qi Wang
Ying Li
Tingting Li
Fangyu Li
Qigeng Wang
Yan Li
Yiping Wei
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Frontotemporal Dementia
Vascular Dementia
Frontotemporal Dementia
Alzheimer's Disease
Dementia
Alzheimer's Disease
Vascular Dementia
Dementia
Biomarkers
Published in: BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-021-02142-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Functional connectivity changes in cerebral small vessel disease - a systematic review of the resting-state MRI literature

The economic value of changing mortality risk in low- and middle-income countries: a systematic breakdown by cause of death

Evaluation of glycemic traits in susceptibility to COVID-19 risk: a Mendelian randomization study

Model-based comorbidity clusters in patients with heart failure: association with clinical outcomes and healthcare utilization

Modification effect of ideal cardiovascular health metrics on genetic association with incident heart failure in the China Kadoorie Biobank and the UK Biobank

Association between thyroid dysfunction and type 2 diabetes: a meta-analysis of prospective observational studies